Literature DB >> 7974189

Survival factors in rhino-orbital-cerebral mucormycosis.

R A Yohai1, J D Bullock, A A Aziz, R J Markert.   

Abstract

Mucormycosis is a highly aggressive fungal infection affecting diabetic, immunocompromised, and, occasionally, healthy patients. This infection is associated with significant mortality. We have reviewed 208 cases in the literature since 1970, 139 of which were presented in sufficient detail to assess prognostic factors, and added data from six of our patients. The histories of these 145 patients were analyzed for the following variables: 1) underlying conditions associated with mucormycotic infections; 2) incidence of ocular and orbital signs and symptoms; 3) incidence of nonocular signs and symptoms; 4) interval from symptom onset to treatment; and 5) the pattern of sinus involvement seen on imaging studies and noted at the time of surgery. Factors related to a lower survival rate include: 1) delayed diagnosis and treatment; 2) hemiparesis or hemiplegia; 3) bilateral sinus involvement; 4) leukemia; 5) renal disease; and 6) treatment with deferoxamine. The association of facial necrosis with a poor prognosis fell just short of statistical significance, but appears clinically important. This is the first review that documents the heretofore intuitive claim that early diagnosis is necessary to cure this disease. Standard treatment with amphotericin B and aggressive surgery are reviewed and adjunctive therapeutic modalities are discussed, including local amphotericin B irrigation, hyperbaric oxygen, and optimizing the immunosuppressive regimen in transplant patients. Hyperbaric oxygen was found to have a favorable effect on prognosis. In addition, possible treatment options for patients with declining renal function are reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974189     DOI: 10.1016/s0039-6257(05)80041-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  83 in total

Review 1.  Neuro-Ophthalmological Emergencies.

Authors:  João Lemos; Eric Eggenberger
Journal:  Neurohospitalist       Date:  2015-10

2.  Fungal Orbital Cellulitis: Presenting Features, Management and Outcomes at a Referral Center.

Authors:  Asim V Farooq; Rakesh M Patel; Amy Y Lin; Pete Setabutr; Juliana Sartori; Vinay K Aakalu
Journal:  Orbit       Date:  2015-04-23

3.  Real-time PCR method for detection of zygomycetes.

Authors:  D Jane Hata; Seanne P Buckwalter; Bobbi S Pritt; Glenn D Roberts; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2008-05-14       Impact factor: 5.948

4.  Predisposing Factors for Mucormycosis in Patients with Diabetes Mellitus; An Experience of 21 Years in Southern Iran.

Authors:  Amene S Sarvestani; Gholamreza Pishdad; Shahram Bolandparvaz
Journal:  Bull Emerg Trauma       Date:  2013-10

Review 5.  Rhinocerebral mucormycosis in a patient with type 1 diabetes presenting as toothache: a case report from Himalayan region of India.

Authors:  Vikram Singh; Mridu Singh; Chitra Joshi; Jyoti Sangwan
Journal:  BMJ Case Rep       Date:  2013-10-30

6.  Secondary vulvar and pulmonary mucormycosis in a trauma patient.

Authors:  J Torcal; J C Salinas; R Lozano; M V Mena; M P Luque; R de Miguel
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

Review 7.  Rhinocerebral mucormycosis: literature review apropos of a rare entity.

Authors:  Carla Alexandra Teixeira; Pedro Bettencourt Medeiros; Pedro Leushner; Fernanda Almeida
Journal:  BMJ Case Rep       Date:  2013-02-05

Review 8.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.

Authors:  Daoud Al-Badriyeh; Chin Fen Neoh; Kay Stewart; David C M Kong
Journal:  Clin Ophthalmol       Date:  2010-05-06

Review 10.  Bench-to-bedside review: oxygen as a drug.

Authors:  Haim Bitterman
Journal:  Crit Care       Date:  2009-02-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.